Announcements
Projects
Orgs
Project
Articles 3
Votes 0
Astrazeneca.com

Authors 1

AstraZeneca
AstraZeneca licenses novel agent for the treatment of cardiometabolic conditions and obesity - AstraZeneca
~2y
Datopotamab deruxtecan met dual primary endpoint of progression-free survival in patients with advanced non-small cell lung cancer in TROPION-Lung01 Phase III trial - AstraZeneca
>2y
Enhertu showed clinically meaningful and durable responses across multiple HER2-expressing tumour types in DESTINY-PanTumor02 Phase II trial - AstraZeneca
almost3y